Drug Profile
Research programme: fibrotic disease therapeutics - Inception 1/Takeda
Latest Information Update: 28 Aug 2020
Price :
$50
*
At a glance
- Originator Inception 1; Shire
- Developer Inception 1; Takeda
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Fibrosis
Most Recent Events
- 28 Aug 2020 No recent reports of development identified for research development in Fibrosis in USA
- 08 Jan 2019 Shire has been acquired and merged into Takeda
- 28 Jul 2016 Early research in Fibrosis in USA (unspecified route)